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Chlamydiae are obligate intracellular bacterial pathogens that replicate solely within a membrane-bound
vacuole termed an inclusion. Within the confines of the inclusion, the replicating bacteria acquire amino acids,
nucleotides, and other precursors from the host cell. Trafficking from CD63-positive multivesicular bodies to
the inclusion was previously identified as a novel interaction that provided essential precursors for the
maintenance of a productive intracellular infection. The present study analyzes the direct delivery of resident
protein and lipid constituents of multivesicular bodies to the intracellular chlamydiae. The manipulation of
this trafficking pathway with an inhibitor of multivesicular body transport and the delivery of exogenous
antibodies altered protein and cholesterol acquisition and delayed the maturation of the chlamydial inclusion.
Although inhibitor studies and ultrastructural analyses confirmed a novel interaction between CD63-positive
multivesicular bodies and the intracellular chlamydiae, neutralization with small interfering RNAs and
anti-CD63 Fab fragments revealed that CD63 itself was not required for this association. These studies confirm
CD63 as a constituent in multivesicular body-to-inclusion transport; however, other requisite components of
these host cell compartments must control the delivery of key nutrients that are essential to intracellular
bacterial development.
Chlamydiae are obligate intracellular bacteria recognized
for their etiologic association with a broad spectrum of clini-
cally distinct manifestations, extending from acute self-limiting
ocular and genital infections to chronic inflammatory diseases
that lead to blindness or infertility. The success of chlamydiae
hinges upon the complex host-pathogen interaction that is
mediated by the invading bacteria. Upon internalization into
the host cell, chlamydiae replicate within a membrane-bound
inclusion. Within this environment, these bacterial pathogens
orchestrate the expansion of the inclusion and the generation/
acquisition of biosynthetic constituents that are essential for
their propagation and subsistence.
Beyond the confines of the inclusion membrane is the nu-
trient-rich host cell cytoplasm. Although chlamydiae remain
largely dissociated from the host cytosol, the recruitment of
key regulators of membrane trafficking (20, 22) and the asso-
ciation with nutrient-rich eukaryotic organelles suggest an in-
teraction that is not passive. Among these interactions is the
intersection of the inclusion with a subset of vesicles originat-
ing from the trans-Golgi network. Golgi-derived sphingomyelin
and cholesterol destined for the plasma membrane are di-
verted to the chlamydial inclusion and are incorporated into
bacterial cell walls (6, 9, 10, 23). In addition, chlamydiae target
lipid droplets, neutral lipid-rich eukaryotic organelles that may
serve as conduits for the transport of essential lipids or vesic-
ular transport proteins to the chlamydial inclusion (18).
The present study focuses on the host cell’s multivesicular
bodies (MVBs) as a source of essential constituents for the
intracellular propagation of Chlamydia trachomatis. MVBs
are lipid- and cholesterol-rich late endocytic organelles that
are pivotal in the segregation of host-derived lipids and
proteins (7, 21). CD63-positive MVBs previously have been
shown to intersect the chlamydial inclusion and provide
lipids that are essential for the maintenance of a productive
intracellular infection (3). Utilizing ultrastructural analyses
and extending inhibitor studies to incorporate small inter-
fering RNA (siRNA) and exogenous Fab fragments, the
intersection between MVBs and intracellular Chlamydia was
confirmed to proceed independently of CD63.
MATERIALS AND METHODS
Reagents. H5C6, a mouse monoclonal antibody against human CD63, and
H4A3, a mouse monoclonal antibody against human LAMP-1, were developed
by J. Thomas August and James E. K. Hildreth (John Hopkins University School
of Medicine, Baltimore, MD) and obtained from the Developmental Studies
Hybridoma Bank/NICHD (University of Iowa, Iowa City). 6C4, a mouse mono-
clonal antibody generated to lysobisphosphatidic acid (LBPA), was generously
provided by Toshihide Kobayashi and Jean Gruenberg (University of Geneva,
Geneva, Switzerland). A57B9, a mouse monoclonal antibody against the chla-
mydial heat shock protein 60 (hsp60), was kindly provided by Richard Morrison
(University of Arkansas, Little Rock). TOPRO-3, Lysotracker Red, and kits for
Alexa Fluor protein labeling and biotin protein labeling were obtained from
Invitrogen (Carlsbad, CA). Filipin and 3--(2-diethylaminoethoxy)-andro-
stenone HCl (U18666A) were obtained from Sigma (St. Louis, MO). Non-
targeting and human CD63-specific siRNAs and DharmaFECT1 were purchased
from Dharmacon, Inc. (Lafayette, CO). Streptavidin gold conjugates were ob-
tained from Ted Pella Inc. (Redding, CA). Fluorescein-conjugated goat anti-
mouse immunoglobulin G (IgG) Fab fragment-specific antibody and colloidal
gold-conjugated anti-mouse IgG (heavy plus light chain) antibodies were pur-
chased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
Chlamydia and cell culture. C. trachomatis serovar E was obtained from
Harlan Caldwell (Rocky Mountain Laboratories, National Institute of Allergy
and Infectious Diseases, NIH) and propagated in HEp-2 cells (ATCC, Manassas,
VA). Elementary bodies (EBs) were purified by Renografin gradient centrifu-
gation as previously described (4). HEp-2 cells were maintained at 37°C with
5.5% CO2 in Iscove’s modified Dulbecco’s medium supplemented with 12.5 mM
HEPES, 10% (vol/vol) fetal bovine serum (FBS), and 10 g/ml gentamicin.
HEp-2 cells were infected by incubating monolayers with Chlamydia EBs at a
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multiplicity of infection of 0.5 for 1 h at 37°C on a platform rocker. Cells were
washed twice with phosphate-buffered saline (PBS) and incubated in Iscove’s
medium for the times indicated.
Immunofluorescence and confocal microscopy. HEp-2 cells were grown on
glass coverslips or on chamber slides and infected with Chlamydia as described
above. For immunofluorescence analysis, antibodies to CD63 and LBPA were
directly conjugated with Alexa Fluor 488 and Alexa Fluor 568, respectively, using
protein-labeling kits obtained from Invitrogen. Infected cells were fixed for 20
min at room temperature in 1% formaldehyde and subsequently treated for 1
min with 1 mg/ml Zwittergent. Fixed and permeable cells then were blocked in
5% goat serum–PBS and incubated with the fluorophore-conjugated primary
antibodies for 20 min. Labeling with individual primary antibodies revealed the
same labeling pattern as that observed with double labeling. Incubation with 0.2
M TOPRO-3 (a monomeric cyanine nucleic acid stain, with an absorbance
wavelength of 642 nm and an emission wavelength of 661 nm) for 10 min at room
temperature labeled both the intracellular bacteria and host cell nuclei. Cover-
slips and slides were mounted using ProLong Anti-Fade mounting medium
(Invitrogen). Images were acquired using a Zeiss LSM510 Meta laser-scanning
confocal microscope (Carl Zeiss Inc., Thornwood, NY) equipped with a 63,
1.4-numerical-aperture Zeiss Plan Apochromat oil objective. Orthogonal Z slices
of 0.5 or 0.8 m through the depth of the inclusion were analyzed, and slices at
the center of the inclusion Z height were acquired. Corresponding intensity
distribution profiles were obtained using the Zeiss LSM510 software.
For the analysis of cholesterol distribution, infected HEp-2 cells were immu-
nolabeled as described above. Following TOPRO-3 labeling, the monolayers
were washed in PBS and incubated with 50 g/ml filipin for 20 min. Coverslips
were mounted as described above and visualized with a Zeiss Axioskop Mot Plus
fluorescence microscope equipped with a 100, 1.4-numerical-aperture Zeiss
Plan Apochromat oil objective. Images were acquired using Axiovision software
(Carl Zeiss Inc).
Electron microscopy. For the analysis of CD63 and LBPA localization at the
ultrastructural level, Chlamydia-infected cells were prepared for cryoimmuno-
electron microscopy. Infected cells were fixed in 4% paraformaldehyde–0.1%
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM piperazine-N,N-
bis(2-ethanesulfonic acid) (PIPES)–0.5 mM MgCl2, pH 7.2, for 1 h at 4°C.
Samples then were embedded in 10% gelatin and infiltrated overnight with 2.3 M
sucrose–20% polyvinyl pyrrolidone in PIPES-MgCl2 at 4°C. Samples were
trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut UCT
cryoultramicrotome (Leica Microsystems Inc., Bannockburn, IL).
For single labeling with anti-CD63 antibody, 50-nm sections were blocked with
5% FBS–5% goat serum for 30 min and then were incubated with the primary
antibody. Sections then were washed in block buffer and probed with anti-mouse
18-nm colloidal gold-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories). For double-labeling experiments, sections were sequentially la-
beled with anti-LBPA followed by anti-mouse 12-nm colloidal gold-conjugated
secondary antibody. Sections then were labeled with biotinylated anti-CD63
antibody followed by streptavidin-conjugated 20-nm colloidal gold. Immunola-
beled sections were washed in PIPES buffer, followed by an extensive water rinse,
and were stained with 1% uranyl acetate–1.6% methyl cellulose (Ted Pella Inc.).
Samples were viewed with a JEOL 1200EX transmission electron microscope
(JEOL USA Inc., Peabody, MA). All labeling experiments were conducted in
parallel, with controls omitting the primary antibody. These controls were con-
sistently negative at the concentration of colloidal gold-conjugated secondary
antibody or streptavidin used in these studies.
Analysis of inhibitors. To analyze the inhibitors, HEp-2 cells were infected
with Chlamydia as described above. One hour postinfection, cells were washed
with PBS and incubated with Iscove’s medium containing 10 M U18666A, an
inhibitor of MVB transport (19), for the 48-h time course of infection. The effects
of inhibitors on inclusion development and morphology were determined by
infectivity assays and immunofluorescence analysis. The effects on cholesterol
trafficking were determined by the analysis of filipin distribution.
RNA interference. HEp-2 cells at subconfluency were transfected with control
(siCONTROL Non-Targeting siRNA no. 1; designated siControl) or CD63-
specific (ON-TARGETplus SMARTpool, human CD63; designated siCD63)
siRNA, using DharmaFECT1 as the transfection agent as described in the
manufacturer’s protocol (Dharmacon, Inc.). Cells transfected for 24 h then were
infected with Chlamydia as described above. One hour postinfection, cells were
subjected to a second transfection and were analyzed at 48 h postinfection by
fluorescence and electron microscopy.
Infectivity assays. At 48 h postinfection, infected monolayers cultured in the
presence of inhibitors were washed with PBS, scraped from the culture dishes
into fresh Iscove’s medium, and sonicated to disrupt the HEp-2 cells and release
infectious EBs. Dilutions of the disrupted cell suspensions were inoculated onto
fresh monolayers of HEp-2 cells as described above. At 48 h postinfection, the
monolayers were fixed, immunolabeled with anti-chlamydial hsp60 antibody, and
visualized with a Zeiss Axioskop Mot Plus fluorescence microscope to quantitate
the number of infection-forming units. Data are presented as the mean infection-
forming units of triplicate cultures  standard deviations (SD). P values were
determined using a t test with a 95% confidence interval.
Exogenous antibody loading. Anti-CD63 Fab fragments were generated and
purified using a mouse IgG1 Fab preparation kit (Pierce Biotechnology, Rock-
ford, IL). Briefly, 1 mg/ml of mouse anti-CD63 IgG1 was dissolved in the
provided digestion buffer, which was supplemented with 10 mM cysteine. The
IgG sample was equilibrated with immobilized ficin protease and purified ac-
cording to the manufacturer’s instructions. Protein A columns were used to bind
Fc fragments and undigested IgG, allowing for the separation of Fab fragments.
Nonreducing sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis
(SDS–10% PAGE) was used to confirm complete digestion to monovalent Fab
fragments and the purity of the preparation.
To minimize the volume of exogenous antibody utilized in these studies,
HEp-2 cells were grown in chamber slides. Untransfected cells, or cells trans-
fected with siControl or siCD63 RNA as described above, were infected with C.
trachomatis. Twenty-four hours postinfection, cells were washed with PBS and
incubated in Iscove’s medium containing 40 g/ml anti-LAMP1 antibody, anti-
CD63 antibody, or purified anti-CD63 Fab fragments. At 48 h postinfection,
where indicated, cells were incubated with 1 M Lysotracker Red for 10 min at
37°C to identify lysosomal compartments. Cells then were fixed and immunola-
beled with Alexa Fluor 488-conjugated mouse antibody or fluorescein-conju-
gated goat anti-mouse IgG Fab fragment-specific antibody to detect the uptake
of exogenous antibodies. For the analysis of cholesterol distribution, cells were
incubated with 50 g/ml filipin for 20 min. Cells then were labeled with
TOPRO-3 and mounted as described above. Orthogonal Z slices of 0.5 or 0.8 m
(wider slices were used because of the lower labeling intensity with fluorescein-
conjugated Fab-specific secondary antibody) through the depth of the inclusion
were analyzed, and slices at the center of the inclusion Z height were acquired.
For the quantitative comparison of the effects of exogenous antibodies on inclu-
sion size, random fields were selected and confocal images of 0.8 m thickness
were obtained. The LSM510 software was used to trace and determine the
cross-sectional area (in square micrometers) of 50 inclusions for each condition.
RESULTS
CD63 and LBPA localize to the chlamydial inclusion in
infected HEp-2 cells. To evaluate the intersection between the
chlamydial inclusion and late endocytic MVBs, the distribu-
tions of two MVB constituents, CD63 and LBPA, were ana-
lyzed in C. trachomatis-infected cells. CD63 and LBPA both
showed specific localization at the site of the chlamydial inclu-
sion by confocal microscopy analysis (Fig. 1), as described
previously (3). This association was demonstrated in HEp-2
cells infected with C. trachomatis serovar E and labeled by
direct immunofluorescence using antibodies specific to these
markers. The confocal analysis of midplane Z sections through
the center of the inclusion revealed a fine punctate pattern at
the site of the chlamydial inclusion (Fig. 1), which colocalized
with TOPRO-3-labeled bacteria within the inclusion. In addi-
tion, TOPRO-3-labeled host cell nuclei did not specifically
label with antibodies to MVBs, providing an internal control
for the level of background label. The distribution of these
markers was shown quantitatively by generating a profile of the
intensity distribution of each constituent along a line traversing
the chlamydial inclusion (Fig. 1). Anti-CD63 and anti-LBPA
antibodies clearly colocalized with TOPRO-3-labeled chla-
mydiae within the profile of the inclusion while being excluded
from the TOPRO-3-labeled host cell nuclei.
The association of CD63 and LBPA with the chlamydial
inclusion is not clearly apparent by confocal microscopy until
36 to 48 h postinfection (3). This indicates that these constit-
uents must accumulate within the inclusion, throughout the
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time course of infection, to levels detectable by this technique.
To confirm the presence of CD63 and LBPA within the chla-
mydial inclusion and to better define this interaction tempo-
rally, infected cells were analyzed at the ultrastructural level
using immunoelectron microscopy. Labeling cryosections of
cells that were infected with Chlamydia for 24 and 48 h with
anti-CD63 and anti-LBPA antibodies revealed the presence of
these constituents within multivesicular organelles adjacent to
the chlamydial inclusion (Fig. 1, lower). In addition, immuno-
labeling clearly showed CD63 and LBPA within the chlamydial
inclusion at both 24 and 48 h postinfection. This association at
the earlier time point of 24 h postinfection indicated that
transport is not a force-driven process that results from the
compression of MVBs at the cell periphery by the expanding
inclusion.
An inhibitor of MVB biogenesis disrupts CD63 transport and
inclusion maturation. The pharmacological agent U18666A in-
hibits lipid transport from late endocytic compartments (19) and
disrupts the trafficking of MVB-associated membrane proteins
(11, 14, 16). A previous analysis of the effect of U18666A on
Chlamydia-infected cells by fluorescence microscopy revealed the
inhibition of CD63 acquisition by the chlamydial inclusion (3). In
this study, the association of CD63 with the chlamydial inclusion
was extended to the ultrastructural level using immunoelectron
microscopy. The labeling of cryosections of cells infected with
Chlamydia for 48 h with anti-CD63 antibodies revealed the pres-
ence of CD63 within multivesicular organelles adjacent to the
chlamydial inclusion in both control and U18666A-treated cells
(Fig. 2). These CD63-positive compartments appeared enlarged
in cross-sections of cells treated with the inhibitor. Immunolabel-
ing clearly showed CD63 within the chlamydial inclusions of con-
trol untreated cells (Fig. 2) but not within the inclusions of
U18666A-treated cells. The U18666A inhibition of CD63 acqui-
sition by chlamydial inclusions correlated with a disruption in the
maturation of the chlamydial inclusion, characterized by a
marked reduction in inclusion size and a decreased yield of in-
fectious progeny (P  0.01) (Fig. 2, right).
An inhibitor of MVB biogenesis disrupts chlamydial growth
and cholesterol acquisition. MVBs are pivotal in the intracel-
lular transport of sphingolipids and cholesterol (21), two host
cell constituents that have been shown to incorporate into the
chlamydial inclusion (5, 6, 10). In the present study, filipin, a
fluorescent polyene antibiotic that binds the 3 hydroxyl group
of steroids, was used to analyze cholesterol distribution in
Chlamydia-infected cells. The photoinstability of this probe
prevents the quantitative detection of cholesterol incorpora-
tion, so analysis relies on comparisons between the different
treatment conditions. Cholesterol was shown to accumulate
at the inclusion membrane at 18 and 48 h postinfection (Fig.
3). The pharmacological agent U18666A inhibits cholesterol
transport from late endocytic compartments (19). Culturing
Chlamydia-infected cells in the presence of 10 M U18666A
for 48 h resulted in the abundant accumulation of cholesterol
in swollen CD63-positive perinuclear compartments (Fig. 3,
lower). Inclusion development was disrupted, as evidenced by
smaller chlamydial inclusions that failed to incorporate detect-
able cholesterol into the inclusion membrane (Fig. 3, lower and
insert). Cholesterol incorporation into inclusions of equivalent
sizes (untreated and 18 h postinfection) (Fig. 3, upper) indi-
cated that this acquisition normally occurs early in develop-
FIG. 1. CD63 and LBPA localize to the chlamydial inclusion by immunofluorescence and immunoelectron microscopy. HEp-2 cells were
infected with C. trachomatis E for 24 and 48 h, immunolabeled with the indicated MVB-specific antibodies, and analyzed by confocal and electron
microscopy. (Upper) Optical sections (0.5 m thick) of infected cells immunolabeled with anti-CD63-Alexa Fluor 488 and anti-LBPA-Alexa Fluor
568. The TOPRO-3 labeling of the equivalent confocal slice identified intracellular bacteria and host cell nuclei (merged image). Arrowheads
identify chlamydial inclusions. The white line in the merged image indicates the position of the profile line used for the analysis of intensity
distribution. Scale bar, 20 m. (Lower) The graph on the left shows that the intensity distribution profiles confirmed that CD63 (green line) and
LBPA (red line) had high intensity values peripheral to the inclusion and also displayed intensity levels above background at the site of the
TOPRO-3-positive (blue line) chlamydial inclusion. The profile through the host cell nuclei indicates the background intensity levels of CD63 and
LBPA. The images on the right show cells that were infected for 24 and 48 h and immunolabeled with anti-LBPA (12 nm colloidal gold) and
anti-CD63 (20-nm colloidal gold) antibodies, revealing the presence of these two constituents adjacent to the chlamydial inclusion within
compartments that morphologically resembled MVBs (arrowheads). CD63 and LBPA also were evident along the inclusion membrane and in small
vesicles within the inclusion lumen (arrows and enlarged in insert). C, Chlamydia. Scale bar, 0.5 m.
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ment but is blocked by U18666A treatment. The disruption of
cholesterol transport to the chlamydial inclusion by the inhi-
bition of trafficking from MVBs suggests that CD63-positive
MVBs provide a novel transport pathway of cholesterol deliv-
ery to intracellular chlamydiae.
MVBs intersect the chlamydial inclusion in the absence of
CD63. To determine if the MVB constituent CD63 is essential
for the interaction of this compartment with the chlamydial
inclusion, RNA interference studies were carried out to block
CD63 synthesis. CD63 and LBPA both showed specific local-
FIG. 2. Inhibitor of MVBs prevents CD63 transport to the chlamydial inclusion. HEp-2 cells were infected with C. trachomatis serovar E,
cultured in the presence of 10 M U18666A for 48 h, and compared to untreated cells that had been infected for 48 h. Infected cells were
immunolabeled with anti-CD63 antibody (18-nm colloidal gold) and analyzed by electron microscopy. CD63 was present within compartments that
morphologically resembled MVBs (arrowheads), which appeared enlarged in U18666A-treated cells. CD63 also was evident along the inclusion
membrane and in small vesicles within the inclusion lumen (arrows and enlarged in inserts) in untreated control cells. CD63 was not identified
within the inclusion of U18666A-treated cells. C, Chlamydia. Scale bar, 0.5 m. The graph on the right shows the reduction in the recovery of
infectious Chlamydia observed in cells cultured in the presence of U18666A, as assessed at 48 h postinfection. Data are presented as the mean
infection-forming units of triplicate cultures  SD.
FIG. 3. Inhibitor of MVBs alters the distribution of cholesterol in Chlamydia-infected cells. HEp-2 cells were infected with C. trachomatis serovar E,
cultured in the presence of 10 M U18666A for 48 h, and compared to untreated infected cells. Infected cells were immunolabeled with anti-CD63
antibody (Alexa Fluor 488) and filipin and analyzed by fluorescence microscopy. TOPRO-3 labeling identified intracellular bacteria and host cell nuclei
(merged image). (Upper) Untreated control cells at 18 h postinfection revealed the incorporation of cholesterol into the membrane of inclusions (arrows
and insert) equivalent in size to those of the inclusions of cells after 48 h of inhibitor treatment. (Middle) Untreated control cells at 48 h postinfection
showed the incorporation of cholesterol into the inclusion membrane (arrows and insert). (Lower) Treatment with U18666A results in the disruption of
chlamydial development and the abundant accumulation of cholesterol in CD63-positive compartments (arrowheads and insert, lower right) with the lack
of the incorporation of cholesterol into the chlamydial inclusion (arrows and insert, center). Scale bar, 20 m.
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ization at the site of the chlamydial inclusion by confocal mi-
croscopy analysis of cells transfected with control siRNA
(siControl). For cells transfected with CD63-specific siRNA
(siCD63) and analyzed at 48 h postinfection, a decrease in host
cell CD63 correlated with a decrease in inclusion-associated
CD63 (Fig. 4, upper). The association of LBPA with perinu-
clear compartments and the chlamydial inclusion were not
altered by siCD63. The distribution of these markers was
shown quantitatively by generating a profile of the intensity
distribution of each constituent along a line traversing the
chlamydial inclusion (Fig. 4, upper).
The intersection of multivesicular compartments with the
chlamydial inclusion was confirmed at the ultrastructural level
by immunoelectron microscopy. The labeling of the cryosec-
tions of cells infected with Chlamydia for 48 h with anti-CD63
and anti-LBPA antibodies revealed the presence of these con-
stituents within multivesicular organelles adjacent to the chla-
mydial inclusion and within the inclusion lumen in siControl
cells (Fig. 4, lower). Cells transfected with siCD63 had minimal
levels of CD63 within multivesicular organelles, with the pro-
tein no longer evident within the chlamydial inclusion (Fig. 4).
However, LBPA was clearly present within the chlamydial
inclusion of siCD63-transfected cells (Fig. 4). Although CD63-
positive compartments intersect the chlamydial inclusion,
RNA interference studies confirmed that CD63 itself was not
required for this interaction.
Chlamydial growth and cholesterol acquisition are not al-
tered in the absence of CD63. To determine if the MVB con-
stituent CD63 is essential for chlamydial inclusion maturation
and cholesterol acquisition, inclusion development and filipin
labeling were analyzed in cells transfected with siCD63. Inclu-
sions appeared to mature normally regardless of CD63 expres-
sion levels (Fig. 5). Cholesterol was incorporated into the in-
clusion membrane of cells deficient in CD63 protein (Fig. 5,
insert). The recovery of infectious progeny at 48 h postinfec-
tion from siCD63-transfected cells appeared to be slightly re-
duced compared to that of control cells; however, this differ-
ence was not statistically significant (P  0.244) (Fig. 5, right).
Therefore, the intersection of MVBs and intracellular chla-
mydiae and the subsequent acquisition of host cell-derived
FIG. 4. siCD63 prevents the acquisition of CD63 by the chlamydial inclusion. At 48 h postinfection, HEp-2 cells transfected with siControl and
siCD63 RNAs were immunolabeled with the indicated MVB-specific antibodies and analyzed by confocal and electron microscopy. (Upper) The
images on the left show 0.5-m-thick optical sections of infected cells immunolabeled with anti-CD63-Alexa Fluor 488 and anti-LBPA-Alexa Fluor
568. The TOPRO-3 labeling of the equivalent confocal slice identified intracellular bacteria and host cell nuclei (merged image). Arrows indicate
transfected cells with decreased levels of CD63. The asterisk indicates an internal untransfected CD63-positive control cell. The white line in the
merged image indicates the position of the profile line used for the analysis of intensity distribution. Scale bar, 20 m. The graphs on the right show
that intensity distribution profiles confirmed that CD63 (green line) and LBPA (red line) had intensity levels above background in a CD63-positive
cell. In cells in which CD63 expression was reduced (arrows in the images on the left), profiles revealed a reduction of CD63 within the inclusions
to background levels with no effect on the levels of LBPA. (Lower) Infected cells immunolabeled with anti-LBPA (12-nm colloidal gold) and
anti-CD63 (20-nm colloidal gold) antibodies revealed the presence of CD63 (circled in green) and LBPA within the inclusion lumen (arrows and
enlarged in insert) in cells transfected with the siControl RNA. In cells transfected with siCD63 RNA, the level of CD63 present in MVBs was
reduced with only LBPA within the inclusion lumen. C, Chlamydia. Scale bar, 0.5 m.
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constituents proceeds in the absence of the MVB-associated
protein CD63.
Internalized exogenous anti-CD63 antibody and Fab frag-
ments traffic to the chlamydial inclusion with disparate effects
on chlamydial development. Previous studies on the neutral-
ization of CD63 using internalized exogenous anti-CD63-spe-
cific antibody revealed an accumulation of the antibody in the
chlamydial inclusion with the concurrent disruption of inclu-
sion development (3). Those studies implied a role for CD63 in
a novel MVB-inclusion interaction and are in contention with
the present siRNA studies, which indicate that CD63 is not
required for this association. To address this discrepancy, it
was essential to confirm that the intracellular accumulation of
endocytosed anti-CD63 antibody, and its subsequent associa-
tion with and alteration of the chlamydial inclusion, was a
consequence of direct binding to and trafficking with its anti-
gen. siRNA studies utilizing cells transfected with siControl or
siCD63 RNA were integrated with the analysis of exogenously
internalized anti-CD63. In siControl cells, confocal microscopy
at 48 h postinfection revealed that exogenously internalized
FIG. 6. siCD63 prevents the acquisition of internalized exogenous anti-CD63 antibody by the chlamydial inclusion. HEp-2 cells transfected with
siControl and siCD63 RNAs were infected with C. trachomatis serovar E and cultured in the presence of exogenous (Exog) anti-CD63 from 24
to 48 h postinfection. (Left) Infected cells labeled with Lysotracker Red and then fixed and immunolabeled with anti-mouse Alexa Fluor 488. The
TOPRO-3 labeling of the equivalent confocal slice identified intracellular bacteria and host cell nuclei (merged image). Optical sections (0.5 m
thick) of cells transfected with siControl RNA revealed that exogenously added anti-CD63 antibody trafficked to and accumulated in TOPRO-
3-positive chlamydial inclusions and resulted in reduced inclusion size (arrows). In cells transfected with siCD63 RNA and with the subsequent
downregulation of CD63 expression (not shown), the exogenous anti-CD63 was excluded from the chlamydial inclusion (arrowheads) and
accumulated in lysosomes (Lysotracker Red positive) with no alteration of inclusion development. The white line in the merged image indicates
the position of the profile line used for the analysis of intensity distribution. Scale bar, 20 m. (Right) Intensity distribution profiles confirmed that
internalized anti-CD63 antibody (green line) displayed intensity levels above background at the site of the TOPRO-3-positive (blue line)
chlamydial inclusion in siControl cells. In siCD63-infected cells, high intensity values for anti-CD63 (green line) localized with Lysotracker Red
(red line) peripheral to the inclusion and host cell nuclei but displayed background intensity levels at the site of the chlamydial inclusion. The
profile of the host cell nuclei indicates the background intensity levels of CD63 and Lysotracker Red.
FIG. 5. siCD63 does not alter the distribution of cholesterol in Chlamydia-infected cells. At 48 h postinfection, HEp-2 cells transfected with
siCD63 RNA were immunolabeled with the indicated anti-CD63 antibody (Alexa Fluor 488) and filipin and analyzed by fluorescence microscopy.
TOPRO-3 labeling identified intracellular bacteria and host cell nuclei (merged image). No difference in the incorporation of cholesterol was
evident in cells in which CD63 expression was reduced (insert) compared to that of control cells within the same field. Arrows indicate chlamydial
inclusions. An asterisk indicates an internal untransfected CD63-positive control cell. Scale bar, 20 m. The graph on the right shows that there
was no significant effect of siCD63 RNA on the recovery of infectious Chlamydia, as assessed at 48 h postinfection. Data are presented as the mean
infection-forming units of triplicate cultures  SD.
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anti-CD63 accumulated in perinuclear vesicular compartments
and within the chlamydial inclusion (Fig. 6, upper). In addition,
smaller inclusions were evident, confirming an effect of exog-
enous anti-CD63 antibody on inclusion development, as de-
scribed previously (3). The analysis of cells transfected with
siCD63, which were subsequently infected with Chlamydia and
exposed to exogenously internalized anti-CD63, revealed vari-
able inclusion sizes. Cells containing small inclusions with the
incorporation of internalized antibody correlated with unal-
tered CD63 expression (data not shown) and expressed a phe-
notype identical to that of the siControl cells. In contrast, in
siCD63-transfected cells, in which there was the subsequent
downregulation of CD63 protein, exogenous anti-CD63 anti-
body did not localize to the chlamydial inclusion or alter in-
tracellular chlamydial development (Fig. 6, lower). The distri-
bution of anti-CD63 antibody was shown quantitatively by
generating a profile of the intensity distribution along a line
traversing the chlamydial inclusion (Fig. 6, right). As predicted,
exogenously internalized anti-CD63 antibody failed to find an
epitope in cells in which CD63 synthesis was blocked, resulting
in endocytic trafficking to, and subsequent accumulation in,
degradative lysosomes (Lysotracker Red positive).
To further analyze the discrepancy in outcome between
these two approaches to neutralize CD63, the effects of exog-
enously internalized monovalent anti-CD63 Fab fragments
were analyzed. Mouse anti-CD63 IgG1 antibody was frag-
mented using immobilized ficin protease, and subsequently
Fab fragments were purified (Fig. 7, left). Exogenously inter-
nalized control antibody (anti-LAMP-1) trafficked to lysoso-
mal compartments (Lysotracker Red positive) with no anti-
body localization to the chlamydial inclusion or alteration in
chlamydial development (Fig. 7, top). Exogenously internal-
ized whole divalent anti-CD63 antibody accumulated in pe-
rinuclear vesicular compartments and within the chlamydial
inclusion, with a concurrent disruption in inclusion develop-
ment (Fig. 7, center). An intermediate phenotype was ob-
served when anti-CD63 Fab fragments were added to Chlamy-
dia-infected cells. The monovalent Fab fragments accumulated
in perinuclear vesicles and within the chlamydial inclusion;
however, in contrast to whole divalent anti-CD63 antibody,
FIG. 7. Internalized exogenous (Exog) anti-CD63 Fab fragments localize to the chlamydial inclusion without the disruption of intracellular
chlamydial development. (Left) A nonreducing SDS-PAGE gel of whole anti-CD63 Ig (150 kDa) and purified anti-CD63 Fab fragments (50 kDa).
(Middle) HEp-2 cells infected with C. trachomatis E and cultured in the presence of the indicated exogenous antibody from 24 to 48 h postinfection.
Infected cells were labeled with Lysotracker Red and then fixed and immunolabeled with fluorescein-conjugated anti-mouse IgG Fab fragment-
specific antibody. The TOPRO-3 labeling of the equivalent confocal slice identified intracellular bacteria and host cell nuclei (merged image).
Optical sections (0.8 m thick) revealed that exogenously added control anti-LAMP-1 antibody was excluded from the chlamydial inclusion
(arrowheads) and accumulated in lysosomes (Lysotracker Red positive). The exogenously added anti-CD63 antibody trafficked to perinuclear
endocytic vesicles that generally did not colocalize with Lysotracker Red but accumulated in TOPRO-3-positive chlamydial inclusions (arrows) and
resulted in reduced inclusion size. The exogenously added anti-CD63 Fab fragments trafficked to perinuclear endocytic vesicles (generally
Lysotracker Red negative) and accumulated in TOPRO-3-positive chlamydial inclusions (arrows) with no alteration in inclusion size. The white
line in the merged image indicates the position of the profile line used for the analysis of intensity distribution. Scale bar, 20 m. (Right) Intensity
distribution profiles of cells treated with control antibody showed high intensity values for anti-LAMP-1 (green line) localized with Lysotracker Red
(red line) peripheral to the inclusion and host cell nuclei but displayed background intensity levels at the site of the chlamydial inclusion. In cells
treated with anti-CD63 antibody or Fab fragments, intensity distribution profiles confirmed that internalized antibody (green line) displayed
intensity levels above background at the site of the TOPRO-3-positive (blue line) chlamydial inclusion. The profile of the host cell nuclei indicates
the background intensity levels of CD63 and Lysotracker Red. Ctrl, control.




arch 18, 2014 by W







there was no evident alteration in inclusion development in
confocal microscopy analyses. A quantitative comparison re-
vealed a mean inclusion size of 538 m2 in the presence of Fab
fragments and 312 m2 with exogenously added whole anti-
CD63 antibody (n  50). The distribution of anti-CD63 anti-
bodies was shown quantitatively by generating a profile of the
intensity distribution along a line traversing the chlamydial
inclusion (Fig. 7, right). These studies indicate that both whole
anti-CD63 antibody and monovalent Fab antibody fragments
retain avidity for CD63 that is encountered within the endo-
cytic pathway and traffic with this host protein. However, the
disruption of inclusion development by undigested antibody
suggests that the larger molecule, with its divalent structure
and Fc portion, sterically hinders the functionality or transport
of other components essential to MVB-to-inclusion delivery
and subsequent inclusion biogenesis.
Internalized exogenous anti-CD63 antibody disrupts chla-
mydial growth and cholesterol acquisition. MVBs are pivotal
in the mobilization of intracellular cholesterol, and the accu-
mulation of anti-CD63 antibody within this compartment may
indirectly interfere with cholesterol transport. To determine if
an interruption in inclusion development by exogenous anti-
CD63 antibody correlated with an interruption in cholesterol
acquisition, inclusion development and filipin labeling were
analyzed in cells cultured in the presence of the exogenous
antibody. In cells cultured with control antibody (anti-LAMP-
1), inclusions matured normally with cholesterol incorporation
into the inclusion membrane (Fig. 8, upper). The internalized
control anti-LAMP-1 antibody trafficked to lysosomal com-
partments with no antibody localization to the chlamydial in-
clusion according to fluorescence microscopy. In infected cells
cultured in the presence of anti-CD63 antibody, as expected,
the exogenous antibody localized to the sites of the C. tracho-
matis cells, and intracellular development was disrupted, as
evidenced by the smaller inclusion size (Fig. 8, lower). How-
ever, under these conditions, the levels of cholesterol incorpo-
ration into Chlamydia and the inclusion membrane were not
detectable by filipin labeling (Fig. 8, lower). The decrease in
cholesterol incorporation in the presence of internalized anti-
CD63 antibody paralleled the results observed with the MVB
inhibitor U18666A (Fig. 3, lower). Both exogenous anti-CD63
antibodies and the MVB inhibitor blocked chlamydial devel-
opment and altered the level of cholesterol incorporation into
the inclusion. The filipin labeling of inclusions of equivalent
size (i.e., for untreated cells and cells at 18 h postinfection)
(Fig. 3, upper) indicated that cholesterol acquisition normally
occurs early in development but is altered in the presence of
exogenously added antibody or U18666A. These studies impli-
cate cholesterol as a potential MVB-derived constituent that is
important in intracellular chlamydial inclusion development.
DISCUSSION
The present study confirms the interaction between a CD63/
LBPA-positive multivesicular compartment and intracellular
chlamydiae with the direct delivery of resident host cell protein
and lipid constituents to the lumen of the bacterial inclusion.
The disruption of trafficking from these CD63-positive MVBs
by a pharmacological inhibitor and exogenously internalized
antibody subsequently reduced protein and cholesterol acqui-
sition by the inclusion and delayed inclusion maturation with a
marked reduction in infectious progeny. Neutralization with
siRNAs and anti-CD63 Fab fragments revealed that CD63
itself was not required for the inclusion’s novel interaction with
lipid and cholesterol acquisition from these multivesicular host
cell compartments. Collectively, these results indicate that
FIG. 8. Internalized exogenous (Exog) anti-CD63 antibody alters the distribution of cholesterol in Chlamydia-infected cells. HEp-2 cells
infected with C. trachomatis serovar E and cultured in the presence of the indicated exogenous antibody from 24 to 48 h postinfection were fixed,
labeled with anti-mouse Alexa Fluor 488 and filipin, and analyzed by fluorescence microscopy. TOPRO-3 labeling identified intracellular bacteria
and host cell nuclei (merged image). (Upper) In cells cultured with exogenously added control anti-LAMP-1 antibody, filipin labeling showed the
incorporation of cholesterol into Chlamydia and the inclusion membrane (arrows and insert). (Lower) Internalization of exogenous anti-CD63
antibody results in the disruption of chlamydial development with the lack of incorporation of cholesterol into the chlamydial inclusion (arrows
and insert). Scale bar, 20 m. Ctrl, control.
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while cholesterol acquisition from MVBs is important for chla-
mydial growth, this process does not depend on CD63.
The tetraspanin protein CD63 is associated with both the
internal vesicles and the limiting membrane of MVBs (8, 13)
and previously was used as a surrogate marker for the analysis
of the intersection of this compartment with the chlamydial
inclusion (3). In parallel to this protein constituent, LBPA, a
lipid highly enriched in internal vesicles of late endocytic mul-
tivesicular compartments (15), was analyzed in this study.
LBPA-rich membranes have been proposed to play a role in
the regulation of the transport of sphingolipids and cholesterol
(14, 17), which are host-derived constituents acquired by the
chlamydial inclusion (5, 6, 10, 24). Quantitative confocal stud-
ies revealed the colocalization of CD63 and LBPA in perinu-
clear compartments and accumulation at the site of the chla-
mydial inclusion (Fig. 1). Analysis at the ultrastructural level
revealed CD63/LBPA-positive multivesicular organelles adja-
cent to the chlamydial inclusion. In addition, immunolabeling
clearly showed CD63 and LBPA within the lumen of the in-
clusion at both 24 and 48 h postinfection. These constituents
often were associated with interlumenal vesicles, implicating a
direct fusion of MVBs with the chlamydial inclusion (Fig. 1).
Chlamydiae acquire host cell sphingomyelin and cholesterol
from Golgi-derived vesicles destined for the plasma membrane
(5, 6, 9, 10). The disruption of transport from the Golgi body
does not completely disrupt chlamydial growth, indicating that
this pathway of acquisition is not exclusive (6, 9). Previous
studies defined an interaction between chlamydiae and MVBs
that is essential for sphingolipid delivery to the maturing chla-
mydial inclusion (3). The present study analyzes MVBs as a
source of cholesterol for the expanding inclusion. As described
by Carabeo et al. (6), the distribution of cholesterol in infected
cells can be visualized by using the fluorescent probe filipin.
The labeling of infected cells with filipin results in the intense
staining of the host cell plasma membrane and the inclusion
membrane. The intracellular chlamydiae stain with a lower
intensity that is difficult to document due to the photoinstabil-
ity of the filipin probe. Here, filipin labeling revealed that the
acquisition of cholesterol by the inclusion was disrupted when
infected cells were cultured in the presence of the MVB in-
hibitor U18666A (Fig. 3). This pharmacological agent inhibits
cholesterol transport from late endocytic compartments (19)
and alters the trafficking of CD63 (11, 15, 16). In infected cells,
U18666A treatment resulted in the dramatic accumulation of
CD63 and cholesterol in enlarged perinuclear vesicles (Fig. 3),
which correlated with the disrupted protein and cholesterol
delivery to the chlamydial inclusion (Fig. 3) and a marked
reduction of infectious progeny at 48 h postinfection (Fig. 2).
A functional role for CD63 in chlamydial inclusion biogen-
esis was suggested previously in studies that targeted the
intracellular trafficking of this protein by using exogenously
internalized anti-CD63-specific antibodies (3). Anti-CD63
antibodies accumulated in perinuclear compartments and sub-
sequently trafficked to and incorporated in the chlamydial in-
clusion, demonstrating a direct interaction between CD63-pos-
itive MVBs and this bacterial compartment. In addition to this
clear association, the exogenous antibody disrupted normal
bacterial growth and inclusion maturation. To determine if the
host cell protein CD63 was essential for the intersection of
MVBs with the chlamydial inclusion, siRNA was used for the
specific targeting and downregulation of CD63 within the in-
fected host cell. Quantitative confocal studies and ultrastruc-
tural analysis revealed that the level of CD63 in MVBs and
subsequent acquisition by the inclusion was dramatically re-
duced in siCD63-transfected cells (Fig. 4). Under these condi-
tions, MVBs devoid of CD63 were clearly shown to intersect
the chlamydial inclusion, with no alteration in host cell lipid or
cholesterol acquisition by the inclusion and minimal effect on
the growth of intracellular Chlamydia or the production of
infectious progeny (Fig. 5). Despite its abundance in MVBs,
siRNA studies confirmed that CD63 itself does not have a
significant functional role in chlamydial inclusion biogenesis
and likely serves as a passive marker in this novel pathway.
The discrepancy between results obtained using different
methods of the neutralization of intracellular CD63 (siRNA
and specific antibody) prompted the reevaluation of exogenous
antibody uptake studies. As described in previous studies (3),
the endocytic uptake of exogenous anti-CD63 antibody re-
sulted in the accumulation of the antibody in the chlamydial
inclusion coinciding with the disruption of inclusion develop-
ment (Fig. 6). This observation is inconsistent with siRNA
studies that clearly indicate that the neutralization of CD63 has
no effect on inclusion maturation (Fig. 4). Therefore, the abun-
dance of CD63 in MVBs, and the mass and divalence of the
binding antibody, likely altered the transport or functionality
of another MVB constituent imperative to nutrient delivery
and inclusion biogenesis. This was confirmed by utilizing Fab
fragments of the anti-CD63 antibody. These small, monovalent
antigen-binding fragments efficiently penetrated the endocytic
pathway and accumulated in late endocytic MVBs and the
chlamydial inclusion (Fig. 7). However, unlike the intact Ig
molecule, and in accordance with the siRNA studies, the Fab
fragments had no effect on chlamydial inclusion development
(Fig. 7). The tetraspanin protein CD63 likely traffics within
contiguous membrane vesicles derived from MVBs, with diva-
lent antibody binding to this protein and subsequently altering
the functionality of adjacent components. The analysis of cho-
lesterol distribution in infected cells treated with exogenous
anti-CD63 antibody revealed a decrease in the accumulation of
cholesterol at the inclusion membrane (Fig. 8). The internal
membranes of MVBs are highly enriched with LBPA, a lipid
thought to play a role in the regulation of the intracellular
transport of cholesterol (13, 14), while the limiting membrane
is enriched in MLN64, a cholesterol binding protein that mo-
bilizes the transport of free cholesterol to acceptor membranes
(1, 2, 12). CD63 is resident in both internal membranes and the
limiting membrane of MVBs (8, 13). The abundance of CD63
and its proximity to MVB constituents essential to the mobi-
lization of cholesterol may account for the effects of anti-CD63
antibody binding on chlamydial development. The potential
role for LBPA and MLN64 in the interaction between CD63-
positive MVBs and intracellular Chlamydia will be analyzed in
ongoing studies.
Chlamydiae have a unique cycle of growth and replication
that is completely contingent upon gaining a position in the
intracellular environment of a eukaryotic host cell. The intri-
cacies of the host cell’s involvement in bacterial growth and
inclusion biogenesis are not completely understood. De novo
host cell protein synthesis is not required at any point during
the developmental cycle; however, host cell-derived biosyn-
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thetic precursors are imperative to the intracellular propaga-
tion and survival of chlamydiae. Obtaining these biosynthetic
constituents from the host cell likely occurs by a multitude of
acquisition mechanisms/strategies. One proposed source of es-
sential constituents is via an interaction with MVBs, which are
dynamic, heterogeneous, intermediate endocytic compart-
ments that intersect the chlamydial inclusion serving as a
source for sphingolipids and cholesterol. Deciphering the in-
tricacies of the MVB and other pathways that allow for the
bacterial acquisition of requisite host-derived constituents will
have important implications on inclusion biogenesis and the
therapeutic targeting of nutrient acquisition pathways that are
crucial to the intracellular growth and subsistence of Chla-
mydia.
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